Short Interest in Valneva SE (NASDAQ:VALN) Expands By 44.0%

Valneva SE (NASDAQ:VALN) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 22,900 shares, an increase of 44.0% from the December 31st total of 15,900 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 41,600 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its position in Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Price Performance

Shares of VALN stock traded up $0.53 during midday trading on Friday, reaching $5.78. 64,274 shares of the company traded hands, compared to its average volume of 36,012. The firm’s 50 day simple moving average is $4.35 and its two-hundred day simple moving average is $5.70. The firm has a market cap of $469.68 million, a PE ratio of -44.46 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Valneva in a research note on Friday.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.